Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Cash Flows (Unaudited)

v3.24.1.1.u2
Condensed Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Cash flows from operating activities      
Net loss $ (4,649,635) $ (4,477,778)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 6,568 5,043 $ 177,398
Stock-based compensation expense 53,434 123,273  
Changes in operating assets and liabilities:      
Accounts receivable 0 (24,638)  
Operating lease right of use assets 28,767 25,380  
Prepaid expenses and other current assets (14,719) (759,312)  
Prepaid research and development 12,395 194,488  
Accounts payable 479,267 (192,095)  
Operating lease liabilities (30,729) (26,276)  
Accrued expenses and other current liabilities 247,634 (840,215)  
Net cash used in operating activities (3,867,018) (5,972,130)  
Cash flows from investing activities      
Purchases of investments - marketable securities (8,432,571) (21,611,032)  
Maturities of investments - marketable securities 5,120,757 15,772,190  
Net cash used in investing activities (3,311,814) (5,838,842)  
Cash flows from financing activities      
Deferred offering costs (30,608) 0  
Proceeds from issuance of common stock, pre-funded warrants and warrants, net of issuance costs 397,607 8,579,023  
Net cash provided by financing activities 366,999 8,579,023  
Net decrease in cash and cash equivalents (6,811,833) (3,231,949)  
Cash and cash equivalents at beginning of year 9,165,179 7,188,553 7,188,553
Cash and cash equivalents at end of year 2,353,346 3,956,604 $ 9,165,179
Supplemental disclosures of cash flow information      
Issuance costs 407,329 1,420,398  
Non cash financing activities      
Deferred offering costs $ 167,721 $ 0